MiNK Therapeutics, Inc. (INKT) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 4 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for INKT is $35.00, representing a +159.1% upside from the current price of $13.51. Price targets range from a low of $35.00 to a high of $35.00.
